Tackling Ocular Surface Disease: Treating Ocular Surface Diseases

Supported by unrestricted educational grants from Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision.

Learning Objectives

Upon completion of this activity, the participant should be able to:

1. Increase confidence in making therapeutic decisions for OSD patients based on disease classification, including acute exacerbations of dry eye disease, chronic dry eye, and MGD
2. Explore approaches to ocular surface toxicity when OSD patients are treated for comorbid conditions

Accreditation and Designation Statement

This course is COPE approved for .5 hour of CE credit for optometrists.

Sponsored by State University of New York School of Optometry Office of Continuing Professional Education

Evolve is an approved COPE Administrator.

COPE Course ID: 67945-AS

COPE Event ID: #119406

Faculty and Disclosures

Douglas K. Devries, OD

Co-Founder and Managing Partner

Eye Care Associates of Nevada

Sparks, Nevada

Marc Bloomenstein, OD, FAAO

Schwartz Laser Eye Center

Scottsdale, Arizona

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Douglas K. Devries, OD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant and Speakers Bureau: Alcon, Bausch + Health, Bio Tissue, Dompe, EyeVance, Johnson & Johnson Vision, Lumeris, Novartis, OcuSoft, Sun, and TearLab, Share/Stockholder: RPS

Marc Bloomenstein, OD, FAAO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, OcuSOFT, Reichert and Sun. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision,  Novartis, and Sun. Research/Grant Support: Allergan. Stock/Shareholder: TearLab.

Editorial Support Disclosures

Erin K. Fletcher, MIT, director of compliance and education; Evolve; and Kate Fehlhaber, PhD, writer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision.